Research progress of CAR-T immunotherapy in solid tumors combined with new strategies
10.11665/j.issn.1000-5048.2023030101
- VernacularTitle:CAR-T新型联用策略治疗实体瘤研究进展
- Author:
Mengyuan LI
1
;
Xiaomeng JIANG
;
Qinyi SUN
;
Wei GUO
Author Information
1. 中国药科大学 生命科学与技术学院
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T-cell (CAR-T);
solid tumor;
antibody drugs;
oncolytic virus;
cancer vaccine;
nano-medicine
- From:
Journal of China Pharmaceutical University
2023;54(4):443-449
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the chimeric antigen receptor T-cell (CAR-T) therapy has achieved breakthrough progress in the treatment of hematologic malignancies. However, when it comes to solid tumors, numerous challenges persist.These include limited CAR-T cell infiltration, susceptibility to T cell exhaustion, off-target effects, and more.Thus, novel therapeutic strategies are imperative to enhance the efficacy of CAR-T therapy for solid tumors. In comparison to standalone CAR-T approaches, the combination of CAR-T with other tumor treatment modalities has demonstrated remarkable effectiveness in both preclinical and clinical research.This review article summarizes the advancements in combining CAR-T with various solid tumor treatments: antibody drugs, oncolytic viruses, tumor vaccines, and nanomedicines.The objective is to furnish a theoretical foundation and novel perspectives for the development of innovative CAR-T combination strategies tailored for solid tumor therapy.
